Srinagar Magazine

Type 2 Diabetes Pipeline Assessment 2022| Insight into the Current Therapies, Emerging Drugs, Treatment, Outlook|Key Companies – Astrazenca, Hanmi Pharmaceuticals, and others

 Breaking News
  • No posts were found

Type 2 Diabetes Pipeline Assessment 2022| Insight into the Current Therapies, Emerging Drugs, Treatment, Outlook|Key Companies – Astrazenca, Hanmi Pharmaceuticals, and others

December 09
18:52 2022
Type 2 Diabetes Pipeline Assessment 2022| Insight into the Current Therapies, Emerging Drugs, Treatment, Outlook|Key Companies - Astrazenca, Hanmi Pharmaceuticals, and others
DelveInsight Business Research LLP
(Las Vegas, Nevada, United States) DelveInsight’s Type 2 Diabetes Pipeline Insight, 2022, covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

(Las Vegas, Nevada, United States) DelveInsight’s Type 2 Diabetes Pipeline Insight, 2022, covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Key Takeaways from the Type 2 Diabetes Pipeline Report

  • Over 100 + companies and 100+ pipeline drugs in Type 2 Diabetes are in various stages of development, and their anticipated acceptance in the Type 2 Diabetes market would significantly increase market revenue. 

  • Leading Type 2 Diabetes companies developing novel drug candidates to improve the Type 2 Diabetes treatment landscape include Hanmi Pharmaceuticals, Eli Lily, AstraZeneca, Oramed Pharmaceuticals, and many others 

  • Promising Type 2 Diabetes pipeline therapies in various stages of development include Sotagliflozin, ORMD080, LY3209590, HM12460A, HM14220, and many others 

 

 

Type 2 Diabetes Overview

Diabetes is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. Diabetes mellitus is of three types Type1, Type 2, and Gestational Diabetes. 

Type 2 diabetes mellitus (T2DM) accounts for around 90% of all cases of diabetes. In T2DM, the response to insulin is diminished, and this is defined as insulin resistance. During this state, insulin is ineffective and is initially countered by an increase in insulin production to maintain glucose homeostasis, but over time, insulin production decreases, resulting in T2DM. T2DM is most commonly seen in persons older than 45 years. Type 2 diabetes primarily occurs as a result of obesity and lack of exercise. Some people are more genetically at risk than others. Type 2 diabetes makes up about 90% of cases of diabetes, with the other 10% due primarily to type 1 diabetes and gestational diabetes. Diagnosis of diabetes is by blood tests such as fasting plasma glucose, oral glucose tolerance test, or glycated hemoglobin (A1C). Type 2 diabetes is typically a chronic disease associated with a ten-year-shorter life expectancy.

 

Type 2 Diabetes Pipeline Analysis: Drug Profile

 

Sotagliflozin: Lexicon Pharmaceuticals

 

Sotagliflozin is an orally-delivered small molecule compound that we are developing for the treatment of heart failure and type 1 and type 2 diabetes. The scientists identified the targets of sotagliflozin, sodium-glucose cotransporter type 1, or SGLT1, and sodium-glucose cotransporter type 2, or SGLT2, in our target discovery efforts based on their discovery that mice lacking SGLT1, SGLT2 or both exhibited potent anti-diabetic phenotypes across multiple measures of glucose control and metabolism in preclinical models. Preclinical studies of sotagliflozin demonstrated that compounds inhibiting both targets had a favorable preclinical profile relative to compounds selective for SGLT2. SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is in the phase 3 stage of development in the treatment of Type 2 Diabetes 

ORMD0801: Oramed Pharmaceuticals

 

Oramed’s oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. Orally administered insulin brings with it enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream.ORMD0801 is in the phase 3 stage of development in the treatment of type 2 Diabetes 

 

Discover more about the emerging Type 2 Diabetes drugs @ Type 2 Diabetes Treatment Drugs

 

Type 2 Diabetes Pipeline Therapies and Key Companies

  • Sotagliflozin: Lexicon Pharmaceuticals

  • ORMD0801: Oramed Pharmaceuticals

  • LY3209590-Eli Lily and Company

  • HM12460A: Hanmi Pharmaceuticals

  • HM14220:Hanmi Pharmaceuticals

 

Type 2 Diabetes Pipeline Therapeutics Assessment– By product, By Route of Administration, By Molecule Type 

Scope of the Type 2 Diabetes Pipeline Report 

  • Coverage: Global 

  • Key Type 2 Diabetes Companies: Eiger BioPharmaceuticals, Zealand Pharma, Hanmi Pharmaceuticals, Crinetics Pharmaceuticals, AmideBio, and others.

  • Key Type 2 Diabetes Pipeline Therapies: Sotagliflozin, ORMD0801, LY3209590, HM12460A, HM14220 and many others 

Find out more about the Type 2 Diabetes treatment options in development @ Type 2 Diabetes Clinical Trials

 

Table of Contents

1. Introduction of Type 2 Diabetes

2. Executive Summary of Type 2 Diabetes

3. Overview of Type 2 Diabetes

4. Pipeline Therapeutics of Type 2 Diabetes

5. Late-Stage Products (Phase III) of Type 2 Diabetes

6. Mid-Stage Products (Phase II) of Type 2 Diabetes

7. Early Stage Products (Phase I/II) of Type 2 Diabetes

8. Preclinical Stage Products of Type 2 Diabetes

9. Discovery Stage Products of Type 2 Diabetes

10. Therapeutic Assessment of Type 2 Diabetes

11. Inactive Products of Type 2 Diabetes

12. Collaborations Assessment- Licensing / Partnering / Funding of Type 2 Diabetes

13. Unmet Needs of Type 2 Diabetes

14. Market Drivers and Barriers of Type 2 Diabetes

15. Appendix 

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/

Related Articles